The latest update is out from Iterum Therapeutics ( (ITRM) ).
Iterum Therapeutics has received FDA approval for ORLYNVAH™, an innovative oral treatment for uncomplicated urinary tract infections (uUTIs) in adult women with limited treatment options. This approval marks a significant milestone as ORLYNVAH™ offers a novel solution to combat antibiotic-resistant infections, showcasing superior efficacy in clinical trials. The company aims to leverage this approval to pursue strategic partnerships or commercialization efforts, addressing a critical need in the market for effective uUTI treatments.
For a thorough assessment of ITRM stock, go to TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
